Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025;25(2):183-203.
doi: 10.2174/0115680096321287240826065718.

Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression

Affiliations

Screening miRNAs to Hinder the Tumorigenesis of Renal Clear Cell Carcinoma Associated with KDR Expression

Rangaraj Kaviyaprabha et al. Curr Cancer Drug Targets. 2025.

Abstract

Introduction: This study delved to understand the role of Kinase Insert Domain Receptor (KDR) and its associated miRNAs in renal cell carcinoma through an extensive computational analysis. The potential of our findings to guide future research in this area is significant.

Methods: Our methods, which included the use of UALCAN and GEPIA2 databases, as well as miRDB, MirDIP, miRNet v2.0, miRTargetLink, MiEAA v2.1, TarBase v8.0, INTERNET, and miRTarBase, were instrumental in identifying the regulation of miRNA associated with KDR expression. The predicted miRNA was validated with the TCGA-KIRC patients' samples by implementing CancerMIRNome. The TargetScanHuman v8.0 was implemented to identify the associations between human miRNAs and KDR. A Patch Dock server analyzed the interactions between hsa-miR-200c-3p and KDR.

Results: The KDR expression rate was investigated in the Kidney Renal Cell Carcinoma (KIRC) samples, and adjacent normal tissues revealed that the expression rate was significantly higher than the normal samples, which was evident from the strong statistical significance (P = 1.63e-12). Likely, the KDR expression rate was estimated as high at tumor grade 1 and gradually decreased till the metastasis grade, reducing the survival rate of the KIRC patients. To identify these signals early, we predicted a miRNA that could alter the expression of KDR. Furthermore, we uncovered the potential associations between miR-200c-3p expressions by regulating KDR towards the progression of KIRC.

Discussion: Upon examining the outcome, it became evident that miR-200c-3p was significantly downregulated in KIRC compared to the normal samples. Moreover, the negative correlation was obtained for hsa-miR-200c-3p (R = - 0.276) along with the KDR expression describing that the increased rate of hsamiR- 200c-3p might reduce the KDR expression rate, which may suppress the KIRC initiation or progression.

Conclusion: The in-silico analysis indicated that the significant increase in KDR expression during the initiation of KIRC could serve as an early diagnostic marker. Moreover, KDR could be utilized to identify advancements in KIRC stages. Additionally, hsa-miR-200c-3p was identified as a potential regulator capable of downregulating and upregulating KDR expression among the 24 miRNAs screened. This finding holds promise for future research endeavors. Concurrent administration of the FDA-approved 5- fluorouracil with KIRC drugs, such as sorafenib, zidovudine, and everolimus, may have the potential to enhance the therapeutic efficacy in downregulating hsa-miR-200c-3p. However, further in vitro studies are imperative to validate these findings and gain a comprehensive understanding of the intricate regulatory interplay involving hsa-miR-200c-3p, KDR, 5-fluorouracil, and other FDA-approved drugs for the treatment of KIRC. This will facilitate the identification of KIRC stage progression and its underlying preventative mechanisms.

Keywords: KDR; computational kidney; miR-200c-3p.; miRNA; renal cell carcinoma; tumor grade potential regulator.

PubMed Disclaimer

Similar articles

Cited by

  • Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategies.
    Hamad RS, Sayed GA, Abd-Elmawla MA, Mageed SSA, Abulsoud AI, Zaki MB, Mohammed OA, Elshaere SS, Elesawy AE, Elkhawaga SY, El-Dakroury WA, Abdel-Reheim MA, Ayed A, Doghish AS. Hamad RS, et al. Int J Clin Oncol. 2025 Aug 21. doi: 10.1007/s10147-025-02856-5. Online ahead of print. Int J Clin Oncol. 2025. PMID: 40839233 Review.

References

    1. Harrison H.; Thompson R.E.; Lin Z.; Rossi S.H.; Stewart G.D.; Griffin S.J.; Usher-Smith J.A.; Risk prediction models for kidney cancer: A systematic review. Eur Urol Focus 2021,7(6),1380-1390 - DOI - PubMed
    1. Li Z.; Xu H.; Yu L.; Wang J.; Meng Q.; Mei H.; Cai Z.; Chen W.; Huang W.; Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Transl Med 2022,12(7),e970 - DOI - PubMed
    1. Lee K.H.; Kim B.C.; Jeong S.H.; Jeong C.W.; Ku J.H.; Kwak C.; Kim H.H.; Histone demethylase LSD1 regulates kidney cancer progression by modulating androgen receptor activity. Int J Mol Sci 2020,21(17),6089 - DOI - PubMed
    1. Brown J.E.; Royle K.L.; Gregory W.; Ralph C.; Maraveyas A.; Din O.; Eisen T.; Nathan P.; Powles T.; Griffiths R.; Jones R.; Vasudev N.; Wheater M.; Hamid A.; Waddell T.; McMenemin R.; Patel P.; Larkin J.; Faust G.; Martin A.; Swain J.; Bestall J.; McCabe C.; Meads D.; Goh V.; Min Wah T.; Brown J.; Hewison J.; Selby P.; Collinson F.; Carser J.; Srinivasan G.; Thistlewaite F.; Azzabi A.; Beresford M.; Farrugia D.; Decatris M.; Thomas C.; Gale J.; McAleer J.; Clayton A.; Boleti E.; Geldart T.; Sundar S.; Lester J.; Palaniappan N.; Hingorani M.; Rehman K.; Khan M.; Sarwar N.; Graham J.; Thomson A.; Srihari N.; Sheehan D.; Srinivasan R.; Khan O.; Jane Worlding A.S.; Boussios S.; Stuart N.; MacDonald-Smith C.; Danwata F.; McLaren D.; Sundaramurthy A.; Lydon A.; Beesley S.; Lees K.; Varughese M.; Gray E.; Scott A.; Baxter M.; Mullard A.; Innominato P.; Kapur G.; Kumar A.; Charnley N.; Manetta C.; Chakraborti P.; Das P.; Rudman S.; Taylor H.; Mikropoulos C.; Highley M.; Muthukumar D.; Zarkar A.; Vergis R.; Sriprasad S.; Brulinski P.; Clarke A.; Osbourne R.; Harvey M.; Dega R.; Sparrow G.; Barthakur U.; Beaumont E.; Manetta C.; Michael A.; Porfiri E.; Azam F.; Kodavtiganti R.; Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): An open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol 2023,24(3),213-227 - DOI - PubMed
    1. Mysliwiec P.; Pawlak K.; Bandurski R.; Kedra B.; Soluble angiogenesis markers in gastric tumor patients. Folia Histochem Cytobiol 2009,47(1),81-86 - DOI - PubMed

MeSH terms

LinkOut - more resources